Form 4: CONMED Director Charles Farkas Exercises Stock Appreciation Rights and Sells Shares for Tax Obligations
Insider Transaction Report
CONMED Corporation Director Charles Farkas exercised 1,000 Stock Appreciation Rights and subsequently sold 966 shares to cover tax liabilities, resulting in a net decrease in his direct common stock holdings.
Summary
- Charles Farkas, a Director of CONMED Corp (CNMD), engaged in transactions on May 29, 2025.
- He exercised 1,000 Stock Appreciation Rights (SARs) at an exercise price of $55.70 per share, acquiring 1,000 shares of common stock.
- These SARs were granted under the Company's 2007 Non-Employee Director Equity Compensation Plan and vested 100% after one year.
- Concurrently, he disposed of 966 shares of common stock at a price of $57.69 per share to satisfy tax withholding obligations related to the SAR exercise.
- Following these transactions, Charles Farkas directly beneficially owns 16,380 shares of CONMED common stock, a decrease from 17,346 shares before the tax-related sale.
- All 1,000 SARs held by Mr. Farkas were exercised, leaving him with 0 SARs.
Sentiment
Score: 5
Explanation: Neutral. The filing reports routine insider transactions related to equity compensation and tax obligations, which is a common occurrence and does not inherently signal positive or negative company performance or outlook.
Positives
- The exercise of Stock Appreciation Rights indicates a realization of value from previously granted equity compensation.
Negatives
- A portion of the acquired shares (966 out of 1,000) was immediately sold, reducing the director's overall direct beneficial ownership in the company.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The stock appreciation rights ("SARs") were granted under the Company's 2007 Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.
Industry Context
This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Power of Attorney | Charles M Farkas granted a Limited Power of Attorney to several individuals within CONMED Corporation, including legal and financial personnel, to execute and file SEC Forms 3, 4, 5, Form 144, and Lock-Up Agreements on his behalf. This streamlines compliance with Section 16(a) of the Exchange Act. | 05/20/2025 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for insider transactions. |
Stakeholder Impact
- Shareholders: The net reduction in direct beneficial ownership by a director, while small and for tax purposes, could be perceived neutrally to slightly negatively, though it's a common practice.
Key Dates
| Date | Description |
|---|---|
| 06/01/2016 | Date SARs became exercisable. |
| 05/20/2025 | Date Limited Power of Attorney was signed and acknowledged by Charles M Farkas. |
| 05/29/2025 | Date of reported transactions (SAR exercise and common stock disposition). |
| 05/30/2025 | Date Form 4 was signed by Power of Attorney. |
| 06/01/2025 | Expiration date of the exercised SARs. |
Recommendation
holdKeywords
CONMED Corp, CNMD, Form 4, Insider Trading, Stock Appreciation Rights, SARs, Equity Compensation, Director Transactions, Share Sale, Tax Withholding, Charles Farkas
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.